ADMA Biologics, Inc. - Q2 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2026. ADMA Biologics, Inc. is a U.S.-based biopharmaceutical company focused on manufacturing and marketing specialty biologics, primarily immune globulins. The company operates two main segments: ADMA BioManufacturing (manufacturing and commercialization of ASCENIV, BIVIGAM, and Nabi-HB) and Plasma Collection Centers (source plasma collection). As of July 31, 2026, there were 223,984,680 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Revenues | $124.4 million | $122.0 million | $238.9 million | $236.8 million |
| Gross Profit | $86.3 million | $67.2 million | $167.0 million | $128.3 million |
| Gross Margin | 69.4% | 55.1% | 69.9% | 54.2% |
| Net Income | $37.8 million | $34.2 million | $83.2 million | $61.1 million |
| Diluted EPS | $0.16 | $0.14 | $0.35 | $0.25 |
| Operating Cash Flow (YTD) | $87.8 million (2026) vs $1.5 million (2025) | |||
| Cash & Equivalents | $136.0 million (as of June 30, 2026) | |||
| Total Debt | $198.1 million (as of June 30, 2026) |
Material Changes vs. Prior Period
- Revenue Mix Shift: Total revenue increased slightly (2.0% QoQ, 0.9% YTD) driven by a 23.5% increase in ASCENIV sales ($102.9M in Q2). This growth was partially offset by a 48.5% decline in BIVIGAM sales ($19.4M in Q2) due to aggressive competitive pricing in the standard IVIG market.
- Margin Expansion: Gross margins improved significantly to 69.4% in Q2 2026 from 55.1% in Q2 2025. This is attributed to favorable product mix (higher ASCENIV volume) and the full impact of an FDA-approved yield enhancement process implemented in 2025.
- Asset Divestiture: The company completed the sale of three plasma collection centers in Q1 2026, recognizing a $8.0 million gain included in YTD operating results. The company now operates seven plasma centers.
- Debt Structure: Total debt increased to $198.1 million from $72.1 million at year-end 2025. This reflects a new $300 million credit facility with JPMorgan (closed Aug 2025) and a $125 million draw in March 2026 to fund an Accelerated Share Repurchase (ASR) agreement.
- Share Repurchases: The company repurchased approximately 13.8 million shares YTD 2026, including 10.8 million shares via the ASR agreement and 3.0 million shares via open market purchases, totaling approximately $156.4 million in cost.
Guidance, Outlook, and Risks
- Outlook: Management expects ASCENIV growth to continue throughout 2026. The yield enhancement process is expected to drive sustained margin expansion. The company anticipates sufficient cash and operating cash flow to fund operations for the next 12 months without raising additional capital.
- Development Pipeline: R&D expenses increased significantly (Q2 2026: $6.0M vs $1.0M Q2 2025) due to the ramp-up of clinical development for SG-001, a hyperimmune globulin for S. pneumoniae. The company plans to submit a pre-IND package in fiscal 2026.
- Competitive Landscape: The filing highlights intense competition in the IVIG market, with new entrants using aggressive pricing tactics (rebates, extended payment terms). This has negatively impacted BIVIGAM sales and created inventory imbalances in the distribution network.
- Legal Proceedings: A putative securities class action lawsuit (Mazzarino v. ADMA Biologics, Inc.) was filed on July 10, 2026, alleging violations of the Securities Exchange Act. The company intends to vigorously defend the action, which is currently in a preliminary stage.
- Supply Chain: The company relies on third-party suppliers for high-titer RSV plasma. It has entered into long-term agreements with Grifols and KEDPlasma to secure supply through the late 2030s.
Investor Verification Checklist
- ASCENIV Growth Sustainability: Verify if the 23.5% sequential growth in ASCENIV is sustainable given the competitive pricing pressures affecting the broader IVIG market.
- BIVIGAM Decline Trajectory: Assess the long-term impact of the 48.5% drop in BIVIGAM revenue and whether the company can stabilize this product line or if it will continue to erode.
- Debt Covenants: Confirm continued compliance with the JPM Credit Agreement covenants (max leverage ratio 2.50:1, min fixed charge coverage 1.20:1) given the increased debt load from the ASR funding.
- SG-001 Progress: Monitor the timeline for the pre-IND submission for SG-001 and the associated R&D burn rate, which has increased significantly.
- Legal Exposure: Track the status of the Mazzarino securities class action lawsuit for potential financial impact or management distraction.
- Customer Concentration: Note that two customers (BioCare and CuraScript) accounted for approximately 81% of accounts receivable as of June 30, 2026, representing a significant concentration risk.